Janux Therapeutics, Inc. (JANX) — Stock Score Summary

Janux Therapeutics, Inc. (JANX) has a MoatMap StockRank of 13/100 based on Quality (39/100), Value (40/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL. Janux Therapeutics is a clinical-stage immunotherapy company. Despite promising early data for its tumor-activated T-cell engagers, it is a binary biotech bet that does not fit our quality compounding or margin of safety criteria.

Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing novel T-cell engager immunotherapies for cancer, utilizing its proprietary Tumour Activated T Cell Engager (TRACTr) platform. The company's innovative TRACTr platform is designed to improve the therapeutic index of T-cell engagers by reducing off-tumor toxicity. It is a niche biopharmaceutical company specializing in next-generation T-cell engager technology for oncology, aiming for safer and more effective cancer treatments.

Key Financial Metrics

Price$13.62
Market Cap$899M
P/E (Forward)-4.96
Price/Book0.89
Return on Equity-11.7%
Return on Invested Capital-16.1%
Debt/Equity2.29
Gross Margin0.0%
Operating Margin-916.5%
Free Cash Flow$-54M

Janux Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Janux Therapeutics, Inc.’s (JANX) StockRank?
MoatMap’s StockRank for Janux Therapeutics, Inc. (JANX) is 13/100, with a Strong Sell signal. It is a composite of Quality (39), Value (40), and Momentum (18) factor ranks across MoatMap’s 19,000+ stock universe.
Does Janux Therapeutics, Inc. have an economic moat?
Janux Therapeutics, Inc. (JANX) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Janux Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Janux Therapeutics, Inc. (JANX) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Janux Therapeutics, Inc. in?
Janux Therapeutics, Inc. (JANX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksJANX deep dive reportAI ChampionsHow we score stocksSense-check another stock